Bioqual, Inc. Reports Earnings Results for the Third Quarter Ended February 28, 2021
April 21, 2021 at 10:19 am EDT
Share
Bioqual, Inc. announced earnings results for the third quarter ended February 28, 2021. For the third quarter, the company announced sales was USD 12.584 million compared to USD 11.593 million a year ago. Net income was USD 975,960 compared to USD 720,406 a year ago. Basic earnings per share from continuing operations was USD 1.09 compared to USD 0.81 a year ago. For the nine months, sales was USD 41.070 million compared to USD 32.884 million a year ago. Net income was USD 4.203 million compared to USD 2.936 million a year ago. Basic earnings per share from continuing operations was USD 4.7 compared to USD 3.29 a year ago.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
